We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Calcific Tendinitis of the Rotator Cuff

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02419040
Recruitment Status : Completed
First Posted : April 17, 2015
Last Update Posted : March 14, 2023
Sponsor:
Collaborators:
Helse Fonna
Oslo University Hospital
Sykehuset i Vestfold HF
Haraldsplass Deaconess Hospital
University Hospital, Linkoeping
Information provided by (Responsible Party):
Stefan Moosmayer, Martina Hansen's Hospital

Brief Summary:
The purpose of this study is to determine whether the combination of removal of the calcification in calcific tendinitis of the shoulder (supraspinatus and/or infraspinatus tendon) by aspiration with a needle and syringe (barbotage) and a corticosteroid injection is more effective than corticosteroid or sham injection alone.

Condition or disease Intervention/treatment Phase
Shoulder Pain Tendonitis Calcinosis Shoulder Impingement Syndrome Procedure: Barbotage Procedure: Corticosteroid injection Procedure: Lidocain injection (sham) Not Applicable

Detailed Description:

Barbotage is a sonographically guided percutaneous needle aspiration and lavage of the calcium deposit in calcific tendinitis of the shoulder. Persisting pain in cacific tendinitis is considered to be a consequence of increased tendon volume or changed tendon texture in the area of the calcification which leads to secondary impingement and inflammation. Consequently, removal of the deposit should be a causal treatment measure.

Scientific evidence for the efficacy of the barbotage procedure in patients with persistent symptoms from calcific tendinitis is still limited. The cyclic often self-limiting course of the disease, and an anticipated placebo effect, questions about the method's efficacy can only be answered by high-quality randomized studies. In this trial the investigators want to randomize a cohort of patients to (1) Ultrasound guided needling, lavage and subacromial steroid injection, (2) Ultrasound guided subacromial steroid injection or (3) Ultrasound guided lidocain injection (sham). The investigators want to follow the patients over two years with repeated testing with a set of validated outcome measures together with radiologic re-examinations. The investigators want to find out whether the active treatments (1, 2) are more effective than the sham treatment and whether there are differences in outcome between the two active treatments. To increase the generalizability of the investigators' results, the investigators want to perform the study as a multi-centre study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 216 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Treatment of Calcific Tendinitis of the Rotator Cuff - a Multi-centre, Randomized and Sham Controlled Trial (KALK Study)
Actual Study Start Date : April 2015
Actual Primary Completion Date : April 2022
Actual Study Completion Date : April 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Barbotage
Ultrasound guided needling, lavage and steroid/lidocain injection (20 mg Triamcinolon/9 ml Lidocain 1%) Ultrasound guided lidocain injection (10 ml Lidocain 1%, sham group) and home exercises
Procedure: Barbotage
A 18-gauge needle connected to a 5 ml syringe with 4 ml of saline solution will be used to puncture the calcification with freehand technique and under constant sonographic monitoring. With the tip of the needle placed in the center of the deposit, the calcification will be flushed. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 9 ml of 1% Lidocain hydrochlorid and 1 ml (20 mg) of Triamcinolon will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
Other Names:
  • 20 mg Triamcinolon/
  • 9 ml Lidocain 1%

Active Comparator: Corticosteroid injection
Ultrasound guided steroid/lidocain injection (20 mg Triamcinolon/9 ml Lidocain 1%) and home exercises
Procedure: Corticosteroid injection
The tip of the 18-gauge needle will be placed in the soft parts outside of the rotator cuff and movements mimicking the lavage procedure will be performed. A lavage procedure usually takes 5 minutes and the same period of time will have to be used for the mimicking maneuver. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 9 ml of 1% Lidocain hydrochlorid and 1 ml (20 mg) of Triamcinolon will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
Other Names:
  • 9 ml Lidocain 1%
  • 20 mg Triamcinolon/

Sham Comparator: Lidocain injection (sham)
Ultrasound guided lidocain injection (10 ml Lidocain 1%, sham group) and home exercises
Procedure: Lidocain injection (sham)
The tip of the 18-gauge needle will be placed in the soft parts outside of the rotator cuff and movements mimicking the lavage procedure will be performed. A lavage procedure usually takes 5 minutes and the same period of time will have to be used for the mimicking maneuver. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 10 ml of 1% Lidocain hydrochlorid will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
Other Name: 9 ml Lidocain 1%




Primary Outcome Measures :
  1. Oxford Shoulder Score [ Time Frame: 4 months ]
    Shoulder pain and disability


Secondary Outcome Measures :
  1. Oxford Shoulder Score [ Time Frame: after 2 and 6 weeks, and 8, 12 and 24 months ]
    Shoulder pain and disability

  2. QuickDASH Disability of shoulder, arm and hand [ Time Frame: after 2 and 6 weeks, and 4, 8, 12 and 24 months ]
    Shoulder pain and disability

  3. EQ 5D-5L [ Time Frame: 4, 8, 12 and 24 months ]
    Health related quality of life

  4. Cross-over of patients [ Time Frame: 4, 8, 12 and 24 months ]
    number of patients crossing over to other group or other treatment

  5. Adverse-events [ Time Frame: 2 and 6 weeks, and 4 months ]
    Patient reported adverse events


Other Outcome Measures:
  1. Size of calcific deposits [ Time Frame: 4 and 24 months ]
    Measured in millimeter AP radiographs

  2. Volume of removed calcific deposit [ Time Frame: Baseline ]
    Volume of removed calcific deposit in milliliter



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. 30 years or older
  2. 3 months or more of shoulder pain
  3. Moderate to strong pain localized on the top and/or lateral side of the shoulder, exaggerated by activities above shoulder level
  4. Painful arc
  5. Positive Hawkin's test and/or Neer's sign for impingement
  6. Finding of one or more calcifications ≥5 mm in size on a standard anteriorposterior radiograph, localized proximally to the greater tubercle, together with a sonographic finding of one or more calcifications ≥5 mm in size on the short or long axis view, localized in the supraspinatus or infraspinatus tendon
  7. Morphological radiographic appearance of Molé type A, B or C12 (appendix 2) A: Dense, homogeneous with well-defined limits B: Dense, fragmented with well-defined limits C: Heterogeneous with poorly defined limits and sometimes with a punctuate appearance
  8. Ability to understand written and spoken Norwegian (Swedish/English)
  9. Existing signed informed consent and expected cooperation of the patients for the treatment and the follow-up

Exclusion criteria:

  1. Clinical and radiological signs of a recent spontaneous release of the deposit such as a sudden change in size or density of the deposit on ultrasound together with an acute onset of extreme shoulder pain
  2. Clinical signs of shoulder instability, glenohumeral arthritis, AC pathology, inflammatory arthropathy, fibromyalgia, frozen shoulder or cervical radiculopathy
  3. Sonographic signs for a rotator cuff tear (full thickness or partial thickness) and of a tear or a dislocation of the long head of the biceps tendon
  4. A history of surgical treatment of the relevant shoulder
  5. A subacromial injection with a corticosteroid during the last 3 months before inclusion
  6. Medical contraindications for any of the invasive procedures
  7. One of the following contraindications for the use of Lidocaine 10 mg/ml: Patients with serious hypovolaemia, known cardiac conduction disturbances, epilepsy or porphyrias, patients with known serious dysfunction of the liver or the kidneys.
  8. One of the following contraindications for the use of Triamcinolone 20 mg/ml: Patients with systemic infections unless specific anti-infective therapy is employed, patients with a local infection in the area of application, patients recently vaccinated with live vaccines, patients with known diabetes mellitus, renal or cardiac insufficiency, ulcerating colitis, gastric ulcer, psychosis, idiopathic thrombocytopenic purpura, or ocular herpes simplex.
  9. Concomitant medication with one of the following medicinal products: Anti-arrythmics such as mexiletine or class III antiarrythmics (e.g. amiodarone), muscle relaxants (e.g. suxamethonium) or antipsychotics (e.g. pimozide, sertindole, olanzapine, quetiapine, zotepine, tropisetrone, dolasetron), antibiotics such as quinopristin/dalfopristin.
  10. Any history of prior allergic/hypersensitivity reactions related to the study medication
  11. Knowledge of an ongoing pregnancy (Fertile women not using contraception and who are uncertain whether they are pregnant or not will have to perform a pregnancy test)
  12. Nursing women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02419040


Locations
Layout table for location information
Norway
Martina Hansen's Hospital
Sandvika, Norway, 1306
Sponsors and Collaborators
Martina Hansen's Hospital
Helse Fonna
Oslo University Hospital
Sykehuset i Vestfold HF
Haraldsplass Deaconess Hospital
University Hospital, Linkoeping
Investigators
Layout table for investigator information
Principal Investigator: Stefan Moosmayer, MD, PhD MHH Martine Hansens Hospital
Publications:
Layout table for additonal information
Responsible Party: Stefan Moosmayer, MD, PhD, Martina Hansen's Hospital
ClinicalTrials.gov Identifier: NCT02419040    
Other Study ID Numbers: KALK-001
First Posted: April 17, 2015    Key Record Dates
Last Update Posted: March 14, 2023
Last Verified: March 2023
Keywords provided by Stefan Moosmayer, Martina Hansen's Hospital:
shoulder pain
rotator cuff
calcific tendonitis
barbotage
Additional relevant MeSH terms:
Layout table for MeSH terms
Shoulder Pain
Tendinopathy
Shoulder Impingement Syndrome
Calcinosis
Arthralgia
Joint Diseases
Musculoskeletal Diseases
Pain
Neurologic Manifestations
Muscular Diseases
Tendon Injuries
Wounds and Injuries
Shoulder Injuries
Calcium Metabolism Disorders
Metabolic Diseases
Lidocaine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action